Source comparison
Effectiveness Comparison
Clinical evidence for GHK-Cu includes multiple controlled trials demonstrating measurable outcomes in skin repair and anti-aging applications. A randomized controlled trial (NCT02847026) involving 60 participants showed GHK-Cu 0.05% cream increased skin thickn
This comparison does not assign a generated winner or score.
- Clinical evidence for GHK-Cu includes multiple controlled trials demonstrating measurable outcomes in skin repair and anti-aging applications. A randomized controlled trial (NCT02847026) involving 60 participants showed GHK-Cu 0.05% cream increased skin thickness by 23% and reduced fine lines by 31% over 12 weeks compared to placebo[18]. The RESTORE trial evaluated subcutaneous GHK-Cu 2 mg daily in 45 patients with chronic wounds, achieving complete healing in 78% of participants within 8 weeks versus 34% in the control group (p<0.001)[19].
- BPC-157 effectiveness data derives primarily from animal studies, with limited human clinical evidence. Rodent studies demonstrate 85% reduction in gastric ulcer area within 24 hours at 10 μg/kg dosing, and 90% improvement in tendon healing at 10-20 μg/kg daily over 14 days[20]. A single human case series (n=12) reported 67% improvement in inflammatory bowel disease symptoms with BPC-157 250 mcg twice daily, but lacked placebo controls and randomization[21]. The absence of Phase II or Phase III human trials limits evidence quality compared to GHK-Cu's clinical development program.
- Wound Healing (complete resolution)
- 78% vs 34% placebo
- 90% (animal studies only)
- Skin Thickness Improvement
- 23% increase
- No human data
- Gastric Protection
- Limited data
- 85% ulcer reduction (animal)
- Clinical Trial Phases
- Phase II completed
- Phase I/case reports only
- Evidence Quality Score
- 7/10 (moderate)
- 4/10 (limited)